| 4.14 -0.22 (-5.05%) | 08-31 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.98 | 1-year : | 5.08 |
| Resists | First : | 4.26 | Second : | 4.34 |
| Pivot price | 4.13 | |||
| Supports | First : | 4.13 | Second : | 3.44 |
| MAs | MA(5) : | 4.13 | MA(20) : | 4.13 |
| MA(100) : | 4.8  |
MA(250) : | 4.85  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 34.9 | |||
| 52-week | High : | 8.1 | Low : | 2.01 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EYES ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.36 - 4.38 | 4.38 - 4.4 |
| Low: | 4.08 - 4.11 | 4.11 - 4.13 |
| Close: | 4.1 - 4.14 | 4.14 - 4.18 |
As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
Tue, 23 Apr 2024
Second Sight Medical Products (EYES) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Movies Canada
Wed, 29 Nov 2023
Second Sight's Argus II Bionic Eye Approved for Medicare Codes - MD+DI
Tue, 15 Aug 2023
Second Sight’s Implant Technology Gets a Second Chance - IEEE Spectrum
Thu, 01 Sep 2022
Second Sight Completes Merger With Nano Precision Medical, Changes Name to Vivani Medical - Vision Monday
Thu, 01 Sep 2022
Second Sight Medical Products completes merger with Nano Precision Medical; and changes name to Vivani Medical - Optics.org
Tue, 30 Aug 2022
Second Sight merges with Nano Precision, rebrands as Vivani - Drug Delivery Business News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 39 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 28.6 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 1,190 (K) |
| Shares Short P.Month | 1,370 (K) |
| EPS | -0.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | -0.56 |
| EPS Est Next Year | -0.52 |
| Book Value (p.s.) | -0.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.8 % |
| Return on Equity (ttm) | -19.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -5.73 |
| PEG Ratio | 0 |
| Price to Book value | -138 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2020-01-05 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|